Dyne Therapeutics Business Summary

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company that operates as a pre-revenue research and development entity focused on advancing targeted genetic medicines for rare neuromuscular diseases. The company currently generates no revenue from product sales, instead funding its operations through equity offerings and strategic capital management while advancing its proprietary FORCE™ platform toward commercialization. This modular technology utilizes antibody-oligonucleotide conjugates (AOCs) to deliver therapeutic payloads—including antisense oligonucleotides (ASOs) and phosphorodiamidate morpholino oligomers (PMOs)—directly to skeletal, cardiac, and smooth muscle tissues. Dyne’s primary business segments are organized around its lead clinical programs: DYNE-101 (zeleciment basivarsen) for myotonic dystrophy type 1 (DM1) and DYNE-251 (zeleciment rostudirsen) for Duchenne muscular dystrophy (DMD), with additional preclinical assets targeting facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. The company competes directly with Avidity Biosciences (recently acquired by Novartis), Arrowhead Pharmaceuticals, Sarepta Therapeutics, and Praxis Precision Medicines, positioning itself as a potential best-in-class leader in muscle-targeted delivery with a targeted first commercial launch in early 2027. The company is led by President and CEO John Cox, an industry veteran who previously served as CEO of Repertoire Immune Medicines and Bioverativ, a rare disease spin-off from Biogen. The executive leadership team includes Chief Medical Officer Doug Kerr, M.D., Ph.D., formerly of Atlas Venture and Generation Bio; Chief Scientific Officer Ranjan Batra, Ph.D., who joined in 2025 from Lexeo Therapeutics; and Chief Commercial Officer Johanna Friedl-Naderer, a former executive at Vir Biotechnology and Biogen. Other key officers include Chief Financial Officer Erick Lucera, Chief Innovation Officer Oxana Beskrovnaya, Ph.D., and Chief Business Officer Vikram Ranade, Ph.D. Dyne was founded by Romesh Subramanian and former CEO Joshua Brumm, and it maintains significant backing from institutional investors including Atlas Venture, T. Rowe Price, and Vanguard. The Board of Directors is chaired by Jason Rhodes, a partner at Atlas Venture, and includes notable members such as Brian Posner, founder of Point Rider Group and former CEO of ClearBridge Advisors.